Table 2_Clinical efficacy of different blood purification modes on severe acute pancreatit

45 randomized controlled trials involving 3,707 patients were included in this systematic review and network meta-analysis. The data, compiled by Peihong Li and last updated in May 2026, evaluates the clinical efficacy of different blood purification modes on Severe Acute Pancreatitis (SAP). It ranks interventions based on outcomes like APACHE II scores, amylase levels, and mortality.

Use Cases

• Ranking blood purification interventions based on APACHE II score reduction mentioned in the results.
• Comparing the efficacy of combined therapies like hemoperfusion plus continuous renal replacement therapy on inflammatory markers (CRP, IL-6).
• Analyzing the impact of different purification modes on specific patient subgroups, such as those with hyperlipidemic SAP, based on triglyceride level outcomes.
• Assessing the relationship between blood purification and mortality outcomes for severe acute pancreatitis.

Strengths

• Includes data from 45 randomized controlled trials.
• Analyzes outcomes for 3,707 patients.
• Uses a defined methodology including risk-of-bias assessment (RoB 2.0) and network meta-analysis.
• Has a registered systematic review protocol (PROSPERO CRD420261403366).

Limitations

• The underlying row-level clinical trial data is not provided; only the analysis results in a document.
• Column-level documentation for the meta-analysis data is absent.
• The dataset is very small at 25.8 KB, indicating limited raw data scope.

Provenance

Source

Systematic review of trials from databases including PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, Wangfang Data, and CBM.

Collection Method

Computerized literature search and network meta-analysis performed with STATA 18.0 using a frequentist framework and random-effects model.

Time Range

Clinical trials published through December 1, 2025.

Freshness

Last updated 2026-05-29 05:31:43